

16 July 2026

Investigational product supply secured for Stabl-Im clinical trial

- Investigational product supply secured to support the planned Phase 1 clinical feasibility trial of the Stabl-Im imaging platform
- Key development milestone supports the Company's targeted commencement of clinical activity in CY2026
- Stabl-Im is an MRI-based functional imaging platform designed to provide information on tumour activity, cell proliferation and treatment response without the use of radioactive tracers
- Clinical development activities continue to advance, including protocol finalisation, preparation of supporting documentation and vendor and clinical site engagement
- The planned study is intended to generate expanded human safety data and preliminary clinical feasibility and imaging performance data for the Stabl-Im platform

Perth, Australia: TrivarX Limited ('the Company') (ASX: TRI) advises that it has secured the investigational product supply required to initiate the Phase 1 clinical feasibility trial of the Company's Stabl-Im imaging platform.

Securing investigational product supply represents an important milestone in the Company's clinical development program and supports the targeted commencement of the Phase 1 clinical trial in CY2026.

The planned study is designed to evaluate the safety of the Stabl-Im approach and generate preliminary data regarding its clinical feasibility and imaging performance. The trial will represent an important evaluation of the technology in humans.

Stabl-Im is TrivarX's MRI-based functional imaging platform designed to provide information on tumour biology using stable isotopes. The platform leverages existing MRI infrastructure and is being developed to provide biologically meaningful information on tumour activity, cell proliferation and treatment response.

Stabl-Im has the potential to complement existing standard-of-care imaging and support improved assessment of tumour biology and response to treatment.

The supply milestone follows the Company's recent engagement of specialist contract research organisation Beyond Drug Development, which is supporting finalisation of the clinical protocol and associated documentation, together with clinical site identification and engagement.

With investigational product supply secured, the Company remains focused on finalising the trial design, selecting clinical sites and completing the regulatory, ethics and operational activities required to commence the study. Commencement of the trial remains subject to completion of these activities and receipt of the necessary ethics and site approvals.

Management commentary:

TrivarX CEO, Dr Danielle Meyrick said: *"Securing investigational product supply is an important milestone as we continue to execute our clinical development strategy for Stabl-Im and underpins progress towards commencement of the planned Phase 1 clinical feasibility trial in CY2026."*

ASX ANNOUNCEMENT



"Together with the recent engagement of Beyond Drug Development, this milestone reflects the steady progress we are making across the clinical, regulatory and operational workstreams required to bring Stabl-Im into the clinic.

"The planned study is a meaningful step in the clinical evaluation of Stabl-IM and is intended to generate expanded human safety data, together with preliminary evidence regarding the platform's clinical feasibility and imaging performance.

"We believe Stabl-Im has the potential to provide valuable information regarding tumour biology and treatment response using existing MRI infrastructure without creating complex clinical workflows."

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX Limited (ASX: TRI) is a healthcare technology company focused on developing innovative diagnostic and imaging solutions across mental health and neuro-oncology. The Company's proprietary technologies include AI-driven algorithms for the detection of mental health conditions using physiological signals, and its Stabl-Im platform, which utilises stable isotope labelling combined with MRI to enable non-invasive imaging of cellular proliferation. Investors can find additional information on www.otcmarkets.com and www.asx.com.au